The finding that MYC is downregulated by GC7 is of particular relevance, as targeting of this oncogene represents a challenging option in cancer therapy and as previous attempts to inhibit this oncogene in CRC with clinically approved translational inhibitors, such as mammalian target of rapamycin inhibitors, have failed41. This evidence concerns the gene MYC and cancer.